10 days ago · New York
US firm ArriVent’s plunge shows risks facing China’s biotech expansion into global markets
What's happening
SignalsMonitor is following this as a general story. South China Morning Post Asia is the outlet attached so far. The reports are tied to New York. The first report grouped here was at 7 Oct 2026, 04:20 UTC. The headline in use is “US firm ArriVent’s plunge shows risks facing China’s biotech expansion into global markets”. This note is SignalsMonitor's own briefing, not the publisher's article.
What we know
US firm ArriVent BioPharma’s shares plummeted after a late-stage trial failure involving a cancer drug licensed from China, a setback that analysts said highlighted the challenges facing Chinese biotech companies expanding overseas. New York-listed ArriVent closed down nearly 47 per cent on Tuesday after reporting that its cancer treatment firmonertinib…
Story timeline
Reports grouped into this story, earliest first. Exact repeats from the same outlet are collapsed.
- First reported by South China Morning Post Asia
US firm ArriVent’s plunge shows risks facing China’s biotech expansion into global markets
Reported by 1 outlet
- South China Morning Post
- South China Morning PostUS firm ArriVent’s plunge shows risks facing China’s biotech expansion into global markets